Coagulation Factor Ix Recombinant Human: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Coagulation Factor Ix Recombinant Human. Educational only — not medical advice.

Labeled uses

RIXUBIS® (Coagulation Factor IX [Recombinant]) is an antihemophilic factor indicated in adults and children with hemophilia B for: On-demand treatment and control of bleeding episodes Perioperative management of bleeding Routine prophylaxis to reduce the frequency of bleeding episodes. RIXUBIS is not indicated for induction of immune tolerance in patients with hemophilia B [see Warnings and Precautions (5.3) ] .

Source: FDA labeling via NIH DailyMed (set f5070a92…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.